The study, published in the
"Previous studies have focused on selected cohorts in an academic setting or tested an unselected population with CKD to determine the prevalence of genetic disorders causing kidney disease," said Anthony
"This study shows that Renasight can help inform CKD prognosis, personalize treatments, inform counseling and testing of at-risk relatives, influence reproductive decision-making, and enable referrals for evaluation of extrarenal manifestations," said
About Renasight
Renasight is a genetic test that uses next-generation sequencing (NGS) and other methodologies to identify germline genetic factors causing or contributing to kidney disease from a patient's blood or buccal sample. The test identifies certain autosomal dominant, autosomal recessive and X-linked disorders, including well-known risk alleles. Providers can use Renasight to identify a genetic predisposition, clarify a clinical diagnosis, or identify the etiology of an unknown kidney disease to help inform medical management. Additionally, genetic counseling and familial testing can be offered based on the test result.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the
Contacts
Investor Relations: Mike Brophy, CFO,
Media: Kate Stabrawa, Communications,
References
- Bleyer AJ, Westemeyer M, Xie J, et al. Genetic Etiologies for Chronic Kidney Disease Revealed through
Next-Generation Renal Gene Panel . Am J Nephrol. 2022 Mar 24:1-10. doi: 10.1159/000522226.
View original content to download multimedia:https://www.prnewswire.com/news-releases/large-real-world-study-with-renasight-genetic-test-highlights-high-diagnostic-yield-for-patients-with-chronic-kidney-disease-301527621.html
SOURCE
The study, published in the
"Previous studies have focused on selected cohorts in an academic setting or tested an unselected population with CKD to determine the prevalence of genetic disorders causing kidney disease," said Anthony
"This study shows that Renasight can help inform CKD prognosis, personalize treatments, inform counseling and testing of at-risk relatives, influence reproductive decision-making, and enable referrals for evaluation of extrarenal manifestations," said
About Renasight
Renasight is a genetic test that uses next-generation sequencing (NGS) and other methodologies to identify germline genetic factors causing or contributing to kidney disease from a patient's blood or buccal sample. The test identifies certain autosomal dominant, autosomal recessive and X-linked disorders, including well-known risk alleles. Providers can use Renasight to identify a genetic predisposition, clarify a clinical diagnosis, or identify the etiology of an unknown kidney disease to help inform medical management. Additionally, genetic counseling and familial testing can be offered based on the test result.
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the
Contacts
Investor Relations: Mike Brophy, CFO,
Media: Kate Stabrawa, Communications,
References
- Bleyer AJ, Westemeyer M, Xie J, et al. Genetic Etiologies for Chronic Kidney Disease Revealed through
Next-Generation Renal Gene Panel . Am J Nephrol. 2022 Mar 24:1-10. doi: 10.1159/000522226.
View original content to download multimedia:https://www.prnewswire.com/news-releases/large-real-world-study-with-renasight-genetic-test-highlights-high-diagnostic-yield-for-patients-with-chronic-kidney-disease-301527621.html
SOURCE